Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 24.4 SEK -2.98% Market Closed
Market Cap: 846.9m SEK

Net Margin
Orexo AB

-37.1%
Current
-28%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-37.1%
=
Net Income
-201.8m
/
Revenue
543.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
Orexo AB
STO:ORX
841.9m SEK
-37%
US
Eli Lilly and Co
NYSE:LLY
1T USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
504B USD
27%
CH
Roche Holding AG
SIX:ROG
252.4B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
210.7B GBP
16%
CH
Novartis AG
SIX:NOVN
206.8B CHF
26%
US
Merck & Co Inc
NYSE:MRK
245.9B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
143B USD
16%
No Stocks Found

Orexo AB
Glance View

Market Cap
841.9m SEK
Industry
Pharmaceuticals

Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

ORX Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-37.1%
=
Net Income
-201.8m
/
Revenue
543.4m
What is the Net Margin of Orexo AB?

Based on Orexo AB's most recent financial statements, the company has Net Margin of -37.1%.

Back to Top